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Background: Korean Red Ginseng extract (KRG, Panax ginsengMeyer) and its constituents have been used
for treating diabetes. However, in diet-induced obese mice, it is unclear whether KRG can enhance the
glucose-lowering action of rosiglitazone (ROSI), a peroxisome proliferator-activated receptor gamma
synthetic activator.
Methods: Oral glucose tolerance tests (oGTTs) were performed after 4 days of treatment with a vehicle
(CON), KRG [500 mg/kg body weight (b.w.)], ROSI (3.75 mg/kg b.w, 7.5 mg/kg b.w, and 15 mg/kg b.w.), or
ROSI and KRG (RK) in obese mice on a high-fat diet. Adipose tissue morphology, crown-like structures
(CLSs), and inﬂammation were compared by hematoxylin-eosin staining or quantitative reverse tran-
scription polymerase chain reaction.
Results: The area under the glucose curve (AUC) was signiﬁcantly lower in the RK group (15 mg/kg b.w.
and 500 mg/kg b.w. for ROSI and KRG, respectively) than in the CON group. There was no signiﬁcant
difference in the AUC between the CON and the other groups. Furthermore, the AUC was signiﬁcantly
lower in the RK group than in the ROSI group. The expression of the Ccl2 gene and the number of CLSs
were signiﬁcantly reduced in the RK group than in the CON group.
Conclusion: Our results show a potential enhancement of ROSI-induced improvement of glucose regu-
lation by the combined treatment with KRG.
Copyright  2016, The Korean Society of Ginseng, Published by Elsevier. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Diabetes mellitus is a chronic disease that causes serious
comorbidities such as neuropathy, nephropathy, and retinopathy.
The global prevalence of diabetes mellitus was estimated at 7.7% in
2010 and continues to increase, especially in low or middle-income
countries, and it is often attributed to a westernized lifestyle and
increasing obesity [1]. Because of the seriousness of this surge in
diabetes, there are intensive efforts to develop novel potent anti-
diabetic agents.
Rosiglitazone (ROSI), a synthetic peroxisome proliferator-
activated receptor gamma (PPARg) agonist, has been used as an
insulin sensitizer for several years. Multiple molecular, tissue-
dependent mechanisms are involved in the insulin-sensitizing ac-
tion of ROSI. For example, the activation of PPARg increases lipidgy, Korea University College of Me
ht  2016, The Korean Society of G
d/4.0/).storage, adipogenesis, lipid metabolism, glucose homeostasis, and
anti-inﬂammatory processes in adipose tissue. It also reduces
gluconeogenesis in the liver and enhances glucose uptake in skel-
etal muscle [2e4]. It was recently found that the release of certain
regulatory factors in adipose tissue such as adiponectin and ﬁbro-
blast growth factor 1 and 21 increased after ROSI treatment and
that these factors have an important role in mediating ROSI’s
insulin-sensitizing effects [2,3]. However, ROSI causes adverse ef-
fects such as weight gain and ﬂuid retention, and it increases the
risk of congestive heart failure and myocardial infarction, based on
meta-analyses of clinical studies [5e7]. This limits the use of ROSI in
the United States and Europe. Further investigation is required
before ROSI can be applied clinically.
Korean Red Ginseng (KRG, Panax ginseng Meyer) is a tradition-
ally prescribed herb in Asian countries such as China, Korea, anddicine, 126-1, 5-Ga, Anam-Dong, Seongbuk-Gu, Seoul 02841, Korea.
inseng, Published by Elsevier. This is an open access article under the CC BY-NC-ND
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function, analgesia, and anticancer and anti-inﬂammatory effects
[8,9]. This pleiotropic trait has often caused KRG to be called an
adaptogen [10]. KRG and some of its constituents such as Re, Rb1,
and Rb2 reportedly have an antidiabetic action in in vitro, animal,
and clinical studies [11,12]. The molecular mechanisms underlying
KRG’s actions have recently been actively investigated; adenosine
monophosphate-activated protein kinase (AMPK) in skeletal mus-
cle has been proposed as a potential target for the KRG-induced
antidiabetic action [13,14].
In this study, we aimed to determine whether KRG has beneﬁ-
cial effects on the ROSI-induced changes in glucose regulation in
obese mice fed a high-fat diet (HFD). Furthermore, we sought to
investigate the underlying mechanism of the improvement of
glucose regulation by analyzing the changes in adipose tissue
morphology and inﬂammation and by comparing the expression of
key energy sensors, including AMP-activated protein kinase
(AMPK) and Protein kinase B (Akt), in skeletal muscle and the liver
in obese mice treated with ROSI and KRG.
2. Materials and methods
2.1. Animals
Seventy-two male C57BL/6 mice (8 weeks old, 21e23 g) were
purchased from Orient Co., Ltd. (Seoul, Korea). The mice were
individually housed in standardmouse cages under a 12-hour light/
dark cycle (lights on at 06:00 AM) and maintained under envi-
ronmentally controlled conditions (22C, 50% relative humidity).
The mice had access to food and water ad libitum, except during the
overnight fast required for the oral glucose tolerance tests (oGTTs),
when only water was freely available. All mice became obese on a
HFD containing 45% fat, 20% protein, and 35% carbohydrates
(4.73 kcal/g, D12451; Research Diets, New Brunswick, NJ, USA),
which they were fed for 12 weeks before the experiments started.
Body weight and food intake were monitored weekly before the
experiments and during the washout periods, and monitored daily
during the experiments. At the end of the experiment, the mice
were sacriﬁced after a 15-hour fast and their blood and tissues were
collected and stored at 80C. All efforts were made to minimize
the number of animals used and animal suffering. All experimental
procedures followed the guidelines on the ethical use of animals,
after all animal protocols were approved by the Institutional Ani-
mal Care and Use Committee of Korea University (Seoul, Korea).
2.2. KRG extract
KRG was manufactured by the Korea Ginseng Corporation
(Seoul, Korea) from the roots of a 6-year-old red ginseng (Panax
ginseng Meyer) harvested in the Republic of Korea. KRG was pro-
duced by steaming fresh ginseng at 90e100C for 3 hours and then
drying it at 50e80C. The KRG water extract was subsequently
prepared by extracting at 85e90C during 8 hours of circulating in
hot water. This procedure was repeated three times. The water
content of the pooled extract was 36% of the total weight. KRG was
analyzed by high-performance liquid chromatography. KRG con-
tained the major ginsenosides Rg1 (2.40 mg/g), Rb1(8.28 mg/g),
Rg1 þ Rb1 (10.67 mg/g), Rg3s (1.12 mg/g), Re (2.48 mg/g), Rc
(3.32 mg/g), Rb2 (2.98 mg/g), Rd (0.88 mg/g), Rf (1.19 mg/g), Rh1
(0.77 mg/g), Rg2s (1.02 mg/g), and other minor ginsenosides.
2.3. Experimental designs
To determine the subthreshold dose of KRG that affects glucose
regulation, we performed oGTTs with KRG [0 mg/kg body weight(b.w.), 125 mg/kg b.w., 250 mg/kg b.w., and 500 mg/kg b.w.] in
obese mice that were fed a HFD for 5 weeks and 11 weeks. Unlike
previous studies [15e17], we did not observe any signiﬁcant dif-
ference in glucose tolerance between the groups at the KRG doses
tested. Therefore, we used 500 mg/kg b.w. of KRG as the sub-
threshold dose for KRG in this study. The obese mice were divided
into four groups: (1) vehicle-treated [i.e., control (CON)]; (2) ROSI-
treated (3.75 mg/kg b.w., 7.5 mg/kg b.w., or 15 mg/kg b.w.); (3)
KRG-treated (500 mg/kg b.w.); and (4) ROSI combined with KRG-
treated (RK; 500 mg/kg b.w. KRG combined with 3.75 mg/kg b.w.
ROSI, 7.5 mg/kg b.w. ROSI, or 15 mg/kg b.w. ROSI) group. During the
experiments, the mice received the vehicle, ROSI, KRG, or RK daily
for 4 days via oral administration. Oral glucose tolerance tests were
performed after an overnight fast on Day 4 of the treatments. Each
experiment was followed by a 3-week washout period.
2.4. Combined oral administration of ROSI and KRG
The vehicle solution for ROSI was prepared by dissolving 0.25 g
of methyl cellulose (Sigma-Aldrich, St. Louis, MO, USA) in 50-mL
deionized water. The ROSI solution was prepared by suspending
ROSI (Cayman Chemicals, Ann Arbor, MI, USA) in the vehicle solu-
tion, which was stirred until the time of administration. The KRG
solution was prepared by dissolving KRG in vehicle (0.9% saline).
The amount of KRG extract was calculated after excluding thewater
content. The ROSI vehicle (0.5% methyl cellulose) or ROSI solution
was administered 1 hour before the administration of the KRG
vehicle (0.9% saline) or the KRG solution, which were administered
before the beginning of the 12-hour dark cycle. All solutions were
prepared daily and administered via gastric gavage.
2.5. Oral glucose tolerance tests
After an overnight fast, we performed oGTTs in the obese mice
on a HFD in accordance with the aforementioned experimental
design. A glucose solution (1.5 g/kg b.w.) was orally administered to
the mice after a 2-hour acclimation period to the experimental
conditions. Glucose levels were determined by tail vein blood
samples using a glucose analyzer (Roche Diagnostics, Mannheim,
Germany) at 0 minutes, 15 minutes, 30 minutes, 45 minutes, 60
minutes, and 120 minutes after the glucose load.
2.6. Measurement of serum insulin levels
Blood samples were collected from the tail vein at 0minutes and
15 minutes during the oGTTs after the glucose load. Serum insulin
levels were subsequently determined using the mouse Ultra Sen-
sitive Insulin ELISA Kit (Crystal Chem, Chicago, IL, USA).
2.7. Quantitative real-time polymerase chain reaction analysis
Obese mice were sacriﬁced during the light phase after a 15-
hour fast started on the last day of the treatments. The epidid-
ymal fat was quickly removed, frozen in 3-methyl butane on dry
ice, and stored at 80C. After the tissue samples were homoge-
nized in TRIZOL reagent (Life Technologies, Carlsbad, CA, USA) and
processed in accordance with the manufacturer’s instructions, the
total RNA was isolated. cDNA was synthesized using iScript reverse
transcription supermix (Bio-Rad, Hercules, CA, USA).
For the quantitative real-time polymerase chain reaction (RT-
qPCR), we used the TaqMan RT-PCR Ready-Mix Kit (PE Applied
Biosystems, Foster City, CA, USA). Gene expression was measured
using an ABI7500 device (Applied Biosystems, Piscataway, NJ, USA).
Forty PCR cycles were performed using a two-step ampliﬁcation
(95C for 10 seconds, annealing temperature at 60C for 30
J Ginseng Res 2017;41:52e5954seconds) using the 7500 software (v2.0.6, Applied Biosystems,
Piscataway). Ribosomal protein L32 was used as an endogenous
control. Mouse primers used are listed in Table S1.
To normalize the data, the DCT (Cycle threshold) was calculated
for each sample by subtracting the CTof L32 from the CTof the gene
of interest. For relative quantization, the DCT was averaged for the
deﬁned control group and was then subtracted from the DCT of
each experimental sample to generate the DDCT. The DDCT was
used to calculate the approximate fold difference, based on the
instructions of Applied Biosystem [18].
2.8. Measurement of hepatic and skeletal glycogen
The levels of hepatic and skeletal muscle glycogen were
measured according to the acid-hydrolysis method [19]. In brief,
after the mice were sacriﬁced, their liver was isolated and stored
at 80C until use. A piece of liver (approximately 10e20 mg) was
transferred into tubes containing 0.5 mL of a 2.0M hydrochloride
solution at 100C. After the tubes were tightly sealed, the samples
were completely hydrolyzed in the same solution at 100C for 1
hour. The hydrolysis products were neutralized with 0.5 mL of a
2.0M sodium hydroxide solution and their glucose concentration
was determined using the manufacturer’s instructions (GAHK-20;
Sigma-Aldrich, St. Louis, MO, USA). In brief, the supernatant was
placed in a microtube containing the enzymatic reagent solution
(1.5mM nicotinamide adenine dinucleotide, 1mM adenosine
triphosphate, 20 U hexokinase, 20 U glucose-6-phosphate dehy-
drogenase, and 20-mL deionized water). The tube contents were
incubated for 15 minutes at room temperature. The absorbance of
the samples was determined using a spectrophotometer (Spec-
traMax Plus384; Molecular Devices, Sunnyvale, CA, USA). The
glucose levels (mmole/g) were adjusted for total volume and tissue
weight.
2.9. Adipose tissue morphometry
For histological analysis, the epididymal fat was ﬁxed for 18
hours in an alcoholic zinc formalin solution at room temperature. It
was then dehydrated by exposure to increasing ethanol concen-
trations (70%, 80%, 90%, 95%, and 100%), and embedded in parafﬁn.
Tissue sections (5 mm) were cut using a microtome (HM 505 E
microtome; Microm Laborgeräte, Walldorf, Germany). After
deparafﬁnization, the sections were stained with Harris’ hema-
toxylin and eosin. To determine the adipocyte size, the cross-
sectional area of adipocytes was measured on sections of epidid-
ymal fat at a 100 magniﬁcation by image processing with
customized software written in Labview 9.0 Student Edition (Na-
tional Instruments, Austin, TX, USA) [18]. Approximately 1,200
adipocytes were analyzed per mouse. The distribution of adipocyte
size was determined by the relative frequencies of adipocytes
having a speciﬁc sizewithin set intervals. The number of crown-like
structures (CLSs) was counted on the same image by four in-
vestigators in a double-blind manner. The density of the CLSs was
calculated by dividing the CLSs by the number of adipocytes on the
same image.
2.10. Western blotting
To investigate the involvement of key energy sensors related to
glucose regulation (e.g., AMPK and Akt) the mice were sacriﬁced
after a 15-hour fast on the last day of the treatments. The phos-
phorylation of AMPK and Akt was measured as previously
described [20]. The liver and skeletal muscle were quickly dissected
and the tissue was homogenized and lysed with radio-
immunoprecipitation assay buffer (1.25% Triton X-100, 0.1% sodiumdodecyl sulfate, 50mM Tris-HCl, 150mM sodium chloride, 5mM
EDTA, pH 7.6) containing a mixture of phosphatase inhibitors, so-
dium ﬂuoride (Sigma-Aldrich, St. Louis, MO, USA), and sodium
pyrophosphate decahydrate (Sigma-Aldrich). Protein (20 mg) was
separated by 10% sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis and electrophoretically transferred to polyvinylidene
diﬂuoride membranes. The membranes were blocked in Tris-
buffered saline (TBS; 10mM Tris, 150mM sodium chloride, pH 8.0)
with 5% skim milk or 1% bovine serum albumin (Sigma-Aldrich). It
was then incubated overnight at 4C with a primary antibody
against phospho-AMPK-alpha (Thr172; 1:1,000), AMPK-alpha
(1:2,000), phospho-Akt (1:1,000), Akt (1:2,000), or beta-actin
(1:4,000). All primary antibodies were purchased from Cell
Signaling Technology (Beverly, MA, USA). After washing in TBS
containing 0.05% Tween-20 (TBST), the membranes were incubated
with a horse radish peroxidase-conjugated secondary antibody
(1:2,000, Cell Signaling Technology) for 1 hour at room tempera-
ture. After further washing in TBST, the proteins were visualized
using an ECL kit (Thermo Scientiﬁc, Rockford, IL, USA). The intensity
of the bands was analyzed using the ImageJ software (National
Institutes of Health, Bethesda, MD, USA) and normalized to the
intensity of an internal control.
2.11. Statistical analysis
The results are displayed as themean the standard error of the
mean. All data from the animal studies were analyzed by two-way
repeated measures analysis of variance (ANOVA), followed by
Bonferroni’s multiple comparisons test; one-way ANOVA followed
by a Fisher’s least signiﬁcant difference test; or a two-tailed Student
t test (GraphPad Prism 5; GraphPad Software Inc., San Diego, CA,
USA). For gene expression and western blotting, a two-tailed Stu-
dent t test was performed. Values of p < 0.05 were considered
statistically signiﬁcant.
3. Results
3.1. The effects of ROSI combined with KRG on body weight and food
intake in diet-induced obese mice
To investigate the effects of ROSI and KRG on body weight and
food intake in obese mice fed a HFD, we compared weight gain and
cumulative food intake for 4 days in the three different RK groups
(500 mg/kg b.w. KRG combined with 3.75 mg/kg b.w. ROSI, 7.5 mg/
kg b.w. ROSI, or 15 mg/kg b.w. ROSI). No signiﬁcant difference in
weight gain and cumulative food intake was observed between the
groups (Fig. 1).
3.2. The effects of ROSI combined with KRG on glucose tolerance
and serum insulin in diet-induced obese mice
To determine the effect of ROSI and KRG on glucose regulation in
obese mice on a HFD, we compared the compounds’ ability to
reduce glucose by performing oGTTs at the three ROSI doses
(3.75 mg/kg b.w., 7.5 mg/kg b.w., or 15 mg/kg b.w.) after 4 days of
treatment.
Time and treatment showed a signiﬁcant correlation with the
change in glucose levels after the glucose challenge between the
treatment groups, as determined by two-way repeated measures
ANOVA (F 15, 170¼ 3.998 for 15 mg/kg b.w. ROSI; p< 0.05; Fig. 2A).
One-way ANOVA revealed a signiﬁcant difference in the area under
the glucose curve (AUC) between the groups at the dose of 15 mg/
kg b.w. ROSI. The AUC was signiﬁcantly lower in the RK group than
in the ROSI group (p < 0.05; Fig. 2B). In the oGTT at the dose of
3.75 mg/kg b.w. ROSI and 7.5 mg/kg b.w. ROSI, similar trends were
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Fig. 1. The effects of rosiglitazone combined with Korean Red Ginseng on body weight
and food intake in diet-induced obese mice. (A) Body weight change during 4 days of
treatment. (B) Percentage change in body weight during 4 days of treatment. (C) Cu-
mulative food intake during 4 days of treatment. Data are presented as mean  the
standard error of the mean. CON, study group treated with 0.5% methyl cellulose and
0.9% saline; KRG, study group treated with 500 mg/kg body weight (b.w.) of Korean
Red Ginseng; RK, study group treated with 500 mg/kg b.w. KRG combined with 15 mg/
kg b.w. rosiglitazone; ROSI, study group treated with 15 mg/kg b.w. of rosiglitazone.
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the glucose-lowering action of ROSI in obese mice fed a HFD.
To determine the responsiveness of insulin secretion to the ac-
tion of ROSI and KRG, we compared the serum insulin levels be-
tween the groups at 0 minutes and 15 minutes after the glucose
load. The basal insulin levels were signiﬁcantly lower in the ROSI
and RK groups, compared to the levels in the CON group, as
measured by one-way ANOVA (F 3, 34 ¼ 4.290 for 15 mg/kg b.w.
ROSI; CON vs. ROSI or RK; p< 0.05; Fig. 2C). However, no signiﬁcant
difference in the insulin levels was observed between the ROSI and
the RK groups. The insulin levels at 15 minutes after the glucose
load were signiﬁcantly lower in the ROSI and the RK groups,
compared to the levels in the CON group, as determined by two-
way repeated measures ANOVA, followed by the Bonferroni mul-
tiple comparisons test (F 3, 34 ¼ 2.270 for 15 mg/kg b.w. ROSI; CON
vs. ROSI or RK; p < 0.05; Fig. 2C). These results indicated that thedemand for insulin in regulating serum glucose levels was
decreased in the ROSI and RK groups, compared to the CON group.
3.3. The effects of ROSI combined with KRG on hepatic and skeletal
muscle glycogen content in diet-induced obese mice
The glycogen levels were signiﬁcantly lower in the liver of the
mice in the RK group that had fasted for 15 hours, compared to the
levels in the liver of the CON animals (p < 0.05; Fig. 3A). However,
no signiﬁcant difference in glycogen levels existed in the skeletal
muscle between the groups (Fig. 3B).
3.4. The effects of ROSI combined with KRG on adipose tissue
morphology and CLSs in diet-induced obese mice
To determine the effect of ROSI and KRG on adipose tissue
morphology, we analyzed adipocyte size andmeasured the number
of CLSs in obese mice on a HFD. After 4 days of treatment, the
number of CLSs was signiﬁcantly different between the groups as
measured by one-way ANOVA (F 3, 28 ¼ 3.019; p < 0.05) and was
signiﬁcantly lower in the RK group than in the CON and KRG groups
(p < 0.05; Fig. 4A and 3B). The cross-sectional area of adipocytes
was signiﬁcantly different between the groups, as shown by one-
way ANOVA (F 3, 28 ¼ 3.709; p < 0.05), and was signiﬁcantly
lower in the RK group than in the ROSI and the KRG groups
(p < 0.05; Figs. 4A, 4E, 4F).
3.5. The effects of ROSI combined with KRG on adipose tissue
inﬂammation in diet-induced obese mice
To determine whether ROSI and KRG affected adipose tissue
inﬂammation, we compared the expression of genes related toType
M1 and M2macrophages including Cd68, Emr1, Ccl2, Ccr2, Itgax, Il6,
Arg1, Jag1, and Chil3.
Unlike the histological ﬁndings, the expression of Emr1 and Cd68
was not signiﬁcantly different between the treatment groups.
However, the expression of Ccl2 was signiﬁcantly lower in the RK
group compared with that in the other groups (p < 0.05 for all
groups; Fig. 4C). By contrast, the expression of Arg1 was signiﬁ-
cantly increased in the ROSI group, compared to its expression in
the CON group (p < 0.05; Fig. 4D), whereas the expression of the
other genes related to Type M1 and M2 macrophages did not
signiﬁcantly differ between the groups.
3.6. The effects of ROSI combined with KRG on the phosphorylation
of AMP-activated protein kinase and Akt in the liver and skeletal
muscle of diet-induced obese mice
The level of AMPK phosphorylation at Thr172 was signiﬁcantly
lower in the liver of the mice in the ROSI and the RK groups
compared to the liver of the animals in the CON group (p < 0.05;
Fig. 5A and 5B); however, no signiﬁcant difference in phosphory-
lation at Thr172 was observed in skeletal muscle. However, neither
ROSI and KRG nor their combination changed Akt phosphorylation
in the liver and skeletal muscle of the obese mice (Fig. 5A and 5B).
4. Discussion
The aim of this study was to determine whether KRG could
enhance the antidiabetic action of ROSI in a diet-induced obesity
animal model. We showed that short-term treatment with KRG
increased the ROSI-induced improvement of glucose regulation in
HFD-fed obese mice. This effect was reﬂected by a lower level of
hepatic glycogen in the fasted obese mice treated with the com-
bination of ROSI and KRG (i.e., the RK group) relative to the other
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tolerance and serum insulin in diet-induced obese mice. (A) Oral glucose tolerance
tests (oGTTs) were performed after 4 days of treatment with ROSI and KRG in obese
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Fig. 3. Effects of rosiglitazone combined with Korean Red Ginseng in diet-induced
obese mice. (A) Effect on hepatic glycogen content. (B) Effect on skeletal muscle
glycogen content. Data are presented as the mean the standard error of the mean. *
p < 0.05. CON, study group treated with 0.5% methyl cellulose and 0.9% saline; KRG,
study group treated with 500 mg/kg body weight (b.w.) of Korean Red Ginseng; RK,
study group treated with 500 mg/kg b.w. KRG combined with 3.75 mg/kg b.w. rosi-
glitazone; ROSI, study group treated with 3.75 mg/kg b.w. of rosiglitazone.
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the level of Ccl2 gene expressionwere signiﬁcantly lower in adipose
tissue of the RK group than in the other groups, which indicated
reduced capability of macrophage recruitment. Furthermore, the
adipocyte size was signiﬁcantly smaller in the RK group than in the
ROSI group and KRG group. However, the activation of AMPK and
Akt in the liver and skeletal muscle that we observed may not have
contributed to the enhancement of the glucose-lowering action in
the RK group.
In this study, we aimed to determine whether the coadminis-
tration of KRG enhances this ROSI-induced improvement of glucose
regulation in obese mice on a HFD, which are glucose-intolerant. To
accomplish this, we administered KRG at a dose that did not
improve glucose regulation. At the highest dose of ROSI we tested
(30mg/kg b.w. ROSI; data not shown), the glucose tolerance of both
groups was better than that of the CON group, whereas no such
difference existed between the ROSI and RK groups. This indicatesthat the effect of KRG on glucose regulation was not sufﬁciently
robust to exceed the potent ability of ROSI (30 mg/kg b.w.) to
improve glucose regulation. However, KRG enhanced the ROSI-
induced improvement in glucose regulation at the lower doses of
ROSI used in this study. We also found that the hepatic glycogen
content was lower only in the fasted RK group relative to that in the
CON group. Because of the absence of increased food intake in both
groups owing to fasting, the similarity in the basal glucose level
between the RK group and the other groups may be attributable to
an increased consumption of stored glycogen in the liver (Figs. 2, 3).
Therefore, the ﬁnding of a lower glycogen content in the RK group
may support the hypothesis of an enhancing ability of KRG on the
glucose-lowering action of ROSI. These results imply that KRG could
be used as an adjuvant in the treatment of diabetics with ROSI.
It has been hypothesized that low-grade adipose tissue
inﬂammation is strongly associated with the development of
obesity and insulin resistance, and that M1 macrophages and
proinﬂammatory cytokines have an important role in insulin
resistance in obese mice [21e23]. Therefore, we investigated the
change in the inﬂammatory status of adipose tissue after the short-
term treatment with RK. We found a reduced number of macro-
phages and Ccl2 expression in adipose tissue of the RK group
compared to the expression in the other groups after this short-
term RK treatment (Fig. 4). Ccl2, a marker of M1 macrophages,
has a critical role in macrophage inﬁltration into adipose tissue and
insulin resistance in obesity [24]. The lower Ccl2 expression in the
RK group may indicate that the number of M1 macrophages was
indeed reduced in adipose tissue, partially underlying the
enhancing effect of KRG on the glucose-lowering action of ROSI.
In Korea, China, and Japan, KRG has traditionally been widely
used to treat inﬂammatory diseases such as chronic gastritis and
colitis [25]. Several lines of evidence on the ability of KRG to
ameliorate inﬂammation have recently been provided at the mo-
lecular level [26,27]. For example, in human gastric epithelial cells
infected with Helicobacter pylori, red ginseng extract suppressed
the induction of Ccl2 expression by inhibiting nicotinamide adenine
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Fig. 4. The effect of rosiglitazone combined with Korean red ginseng on adipose tissue morphology and crown-like structures (CLSs) in diet-induced obese mice. (A) Representative
ﬁgures of epididymal fat after 4 days of treatment (red arrows indicate CLSs of macrophages. (B) Comparison of CLSs per ﬁeld. (C) Ccl2 gene expression in adipose tissue. (D) Arg1
gene expression in adipose tissue. (E) Comparison of the mean surface area of adipocytes. (F) The distribution of adipocyte size. Data are presented as the mean the standard error
of the mean. * p < 0.05. Ccl2 (MCP-1), chemokine (CeC motif) ligand 2; CON, study group treated with 0.5% methyl cellulose and 0.9% saline; KRG, study group treated with 500 mg/
kg b.w. of Korean Red Ginseng; RK, study group treated with 500 mg/kg b.w. KRG combined with 3.75 mg/kg b.w. rosiglitazone; ROSI, study group treated with 3.75 mg/kg b.w. of
rosiglitazone.
M.-J. Oh et al / KRG enhances the action of rosiglitazone 57dinucleotide phosphate oxidase and Jak2/Stat3 activities [27]. In
RAW264.7 cells treated with lipopolysaccharide, KRG water extract
reduced inﬂammatory responses such as the gene expression of
interferon-beta, cyclooxygenase-2, and inducible nitric oxide syn-
thase [26]. In human keratinocytes stimulated by lipopolysaccha-
rides, KRG decreased the secretion of tumor necrosis factor-alpha
and interleukin-8 [28]. Because of the evidence of the anti-
inﬂammatory action of KRG, we hypothesized that KRG per se
may reduce the increased inﬂammatory status in the adipose tissue
of obese mice. We did not observe a change in adipose tissueinﬂammation in obese mice after the short-term treatment with
KRG at the dose we used. However, when obese mice were coad-
ministered ROSI and KRG, the number ofmacrophage clusters along
with Ccl2 gene expression was signiﬁcantly lower than in the other
groups. The underlying mechanisms remain to be determined;
however, the rapid reduction in these macrophage clusters and
Ccl2 gene expression may contribute to the enhancement of
improved glucose regulation in the RK group by reducing the
proinﬂammatory status of the adipose tissue of the obese mice
(Fig. 6).
AB
Fig. 5. The effect of rosiglitazone combined with Korean Red Ginseng on the phosphorylation of adenosine monophosphate-activated protein kinase (AMPK) and Akt in diet-
induced obese mice. (A) The effect in the liver. (B) The effect in the skeletal muscle. Data are presented as the mean the standard error of the mean. * p < 0.05. CON, study
group treated with 0.5% methyl cellulose and 0.9% saline; KRG, study group treated with 500 mg/kg body weight (b.w.) of Korean Red Ginseng; RK, study group treated with
500 mg/kg b.w. KRG combined with 3.75 mg/kg b.w. rosiglitazone; ROSI, study group treated with 3.75 mg/kg b.w. of rosiglitazone.
J Ginseng Res 2017;41:52e5958It is interesting that we observed a signiﬁcant decrease in
adipocyte size in the RK group, compared to the adipocyte size in
the ROSI group. Because of the increased number of smaller adi-
pocytes after ROSI treatment, which was reported in a previous
study [29], the smaller adipocyte size we observed in the RK group
relative to that in the ROSI group may partly explain the enhancing
ability of KRG in the antidiabetic action of ROSI.
To further investigate the mechanisms underlying the bene-
ﬁcial action of the combined treatment with ROSI and KRG in
glucose regulation, we focused on the change in the activation of
AMPK and Akt in skeletal muscle. Long-term administration of
KRG improved glucose tolerance by stimulating fatty acid
oxidation through the activation of AMPK and the phosphoryla-
tion of acetylecoenzyme A carboxylase in skeletal muscle of
Otsuka LongeEvans Tokushima Fatty rats [14,17]. In addition, the
long-term treatment with KRG increased insulin sensitivity viatolerance
tolerance
Fig. 6. Potential mechanism underlying the beneﬁcial action of the combined treat-
ment with rosiglitazone (ROSI) and Korean Red Ginseng (KRG) on glucose regulation.
KRG may enhance the glucose-lowering action of ROSI by reducing adipocyte size and
macrophage recruitment in the adipose tissue of obese mice on a high-fat diet. AT,
adipose tissue.activating IR/IRS-1/Akt/Glut4 signaling in skeletal muscle of diet-
induced obese rats [17]. Because of the critical role of AMPK and
Akt on improving glucose regulation induced by KRG, we hy-
pothesized that the activation of AMPK or Akt in skeletal muscle
may have a key role in the enhanced action of KRG in the ROSI-
induced improvement of glucose regulation. However, we did not
observe any signiﬁcant change in AMPK and Akt activities in
skeletal muscle after 4 days of treatment with RK and ROSI,
compared to the CON treatment. Therefore, this implies that
other mechanisms may be involved in the improved glucose
regulation by AMPK and Akt after the short-term treatment
with RK.5. Conclusion
In summary, this study provides evidence of the enhancement
of the action of ROSI on glucose regulation by coadministering KRG.
This effect may be attributable to the rapid inhibition of macro-
phage recruitment, accompanied by lower Ccl2 gene expression
and smaller adipocytes (Fig. 6). This study raises the potential for
applying ROSI in combination with KRG as an adjuvant. Based on
these results, further studies are required for the development of a
clinical application of this combination drug therapy in diabetic
patients. Therefore, we propose that further detailed investigations
would enable KRG to be a useful choice with ROSI for treating
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